Longer Gaps Between Tarlatamab Doses Show Promise in Small Cell Lung Cancer

Patients with small cell lung cancer who have already undergone platinum-based chemotherapy may soon have more flexibility in how they receive one of the field’s most promising new immunotherapies. Results from the randomized Phase 2 DeLLphi-309 study, presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer in Seoul, suggest that stretching the interval between doses of tarlatamab from two weeks to three or even four weeks preserves most of the drug’s clinical activity while maintaining a safety profile consistent with the established regimen.

Tarlatamab is a bispecific T-cell engager, a designed molecule that simultaneously binds DLL3, a protein abundant on small cell lung cancer cells, and CD3 on T cells, physically drawing immune effector cells into contact with tumor cells and triggering cancer cell killing. When administered at 10 mg every two weeks, the drug has previously demonstrated superior overall survival compared with chemotherapy in patients whose disease had progressed after first-line treatment, a milestone that reshaped expectations for this notoriously aggressive malignancy. The central question of DeLLphi-309 was whether less frequent administration, at higher individual doses, could deliver comparable outcomes while easing the burden of frequent clinic visits.

In the trial, adults whose small cell lung cancer had progressed or recurred after first-line platinum-based chemotherapy were randomized to one of three intravenous regimens: 10 mg every two weeks, 20 mg every three weeks, or 30 mg every four weeks, each following a 1 mg step dose designed to mitigate initial immune-related toxicity. The primary endpoint was confirmed objective response rate as assessed by blinded independent central review. No formal statistical hypotheses were prespecified, and the findings were presented descriptively, meaning the results should be interpreted as exploratory rather than definitive comparative evidence.

As of May 7, 2026, 252 patients had been randomized across the three arms. Blinded independent central review confirmed objective response rates of 40% in the every-two-week group, 31% in the every-three-week group, and 27% in the every-four-week group. Investigator-assessed response rates told a somewhat more compressed story, at 36%, 37%, and 31%, respectively, highlighting how assessment methodology can influence the apparent magnitude of differences between schedules. Median progression-free survival by blinded independent central review was 4.2 months with the established every-two-week regimen, 4.1 months with the every-three-week schedule, and 2.7 months with the every-four-week schedule.

Overall survival data, while immature, added further nuance to the picture. Six-month overall survival rates were 72% with the every-two-week regimen, 85% with the every-three-week regimen, and 69% with the every-four-week regimen. Median overall survival had not yet been reached or estimated after approximately nine months of median follow-up across the three regimens, leaving the most consequential endpoint of all still open to maturation. The apparent survival advantage in the every-three-week arm, in particular, will require longer observation before any conclusions can be drawn.

Safety findings were broadly reassuring. Treatment-emergent and treatment-related adverse event rates were similar across the three dosing regimens, and investigators identified no new or unexpected safety signals. Cytokine release syndrome, the flu-like immune activation event characteristic of T-cell engagers, occurred in 60% to 70% of patients across arms but was predominantly grade 1 or 2 in severity. Immune effector cell-associated neurotoxicity syndrome, a rarer neurological toxicity, was observed in 6% to 12% of patients. Both events were numerically somewhat more frequent in the extended-interval arms, a pattern the researchers noted but did not attribute to a clear mechanism.

Pharmacokinetic analyses offered a mechanistic explanation for why the extended schedules worked as well as they did. Steady-state trough concentrations of tarlatamab were comparable across the three dosing schedules, indicating that increasing the individual dose from 10 mg to 20 mg or 30 mg successfully compensated for the longer gap between administrations. This dose-interval symmetry reflects the drug’s pharmacokinetic behavior, in which total drug exposure over time, rather than the frequency of administration per se, appears to drive both efficacy and tolerability.

Jonathan Goldman, M.D., of the University of California Los Angeles, who presented the findings, emphasized the practical implications. The data suggest that the 20 mg every-three-week and 30 mg every-four-week regimens may offer treatment flexibility for patients with small cell lung cancer, and that alternative dosing schedules for bispecific T-cell engagers generally may achieve outcomes consistent with an established regimen. For patients, fewer clinic visits can translate into less travel, reduced time away from home, and a treatment rhythm that is easier to sustain over months of therapy.

Small cell lung cancer accounts for roughly 10 to 15 percent of lung cancers and is characterized by rapid growth and early dissemination. Although initial platinum-based chemotherapy is often effective, relapse is nearly universal, and options in the second-line setting have historically delivered modest benefit. The arrival of tarlatamab marked the first meaningful expansion of the treatment arsenal in decades, and refining how the drug is delivered could extend its reach to patients for whom biweekly dosing is impractical.

The DeLLphi-309 results arrive amid a broader reassessment of how novel immunotherapies are scheduled. As experience with bispecific antibodies accumulates across hematologic and solid malignancies, investigators are increasingly testing whether dose intensity can be traded for convenience without sacrificing efficacy. For tarlatamab, the descriptive nature of these findings means longer follow-up and additional study will be needed to confirm whether extended-interval dosing can formally match the established every-two-week standard, but for a patient population with few options and significant treatment burdens, the prospect of a three- or four-week schedule represents a meaningful step toward more humane cancer care.

Subject of Research: Extended-interval tarlatamab dosing in previously treated small cell lung cancer evaluated in the Phase 2 DeLLphi-309 trial

Article Title: Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer

Article References: Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: tarlatamab, small cell lung cancer, DeLLphi-309, bispecific T-cell engager, DLL3, cytokine release syndrome, ICANS, dosing schedule, IASLC, WCLC 2026, immunotherapy, progression-free survival